Bristol‑Myers Squibb CFO unloads $4.5 M in shares, insiders net sellers

Over the last year Bristol‑Myers Squibb (BMY) has seen a complete absence of insider buying, contrasted with four sell transactions that total $4,517,215. The resulting buy‑sell ratio of 0.00x sits well below the 0.2x threshold that typically flags heavy insider selling. While such selling can stem from routine equity‑compensation events, the concentration of sales in the CFO’s hands suggests a more material motive.

David V. Elkins, the company’s chief financial officer, executed three separate sales. On September 2, 2025 he sold 56,000 shares for $2,650,480, and on April 1, 2026 he sold two blocks—25,519 shares for $1,571,970 and 4,481 shares for $278,046. Together these trades represent 98.5% of all insider sell value for the period. The only other sale came from Wendy Short, a senior vice‑president, who disposed of 378 shares for $16,719 in August 2025.

The timing of the CFO’s sales aligns with two distinct spikes in the monthly timeline: a $2.65 million sell in September 2025 and a $1.85 million sell in April 2026. No insider purchases were recorded in any month, and the only buying activity in the prior 12 months occurred in late 2024 and early 2025, well before the large sales. This pattern eliminates the possibility of a coordinated buying‑selling cycle and underscores a unilateral exit by the CFO.

From a market perspective, BMY’s stock is trading at $59.47, just 0.13% down on the day, with a 52‑week range position of 83% and a relative strength index of 68, indicating the price is near the upper end of its recent range. The company’s year‑to‑date return of 11.5% and a market cap of $121.4 billion suggest solid performance, yet the insider sell pressure comes at a point when the stock is relatively elevated.

Insider activity of this magnitude—over $1 million in a 12‑month window—crosses the materiality threshold used by analysts. The CFO’s role amplifies the signal, as C‑suite trades are weighted more heavily than those of directors or minor owners. While the sales could be linked to pre‑planned stock‑based compensation vesting, the lack of any offsetting purchases and the clustering of two large sales within a six‑month span merit close monitoring. Investors should watch for any subsequent insider transactions, especially any buying that might counterbalance the current net‑selling stance, and consider the CFO’s exits when assessing the stock’s forward outlook.